AbbVie (ABBV) Stock Forecast & Price Target

Compare

22,604 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABBV Analyst Ratings

Moderate Buy

13 Buy

6 Hold

0 Sell

Based on 19 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$212.13

▲(13.23%Upside)

Based on 19 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $212.13 with a high forecast of $250.00 and a low forecast of $170.00. The average price target represents a 13.23% change from the last price of $187.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"154":"$154","251":"$251","178.25":"$178.3","202.5":"$202.5","226.75":"$226.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$250.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":212.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$212.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$170.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[154,178.25,202.5,226.75,251],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,191.83692307692309,196.68384615384616,201.53076923076924,206.3776923076923,211.2246153846154,216.07153846153847,220.91846153846154,225.76538461538462,230.6123076923077,235.45923076923077,240.30615384615385,245.15307692307692,{"y":250,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,188.92384615384617,190.8576923076923,192.79153846153847,194.72538461538463,196.65923076923076,198.59307692307692,200.52692307692308,202.46076923076924,204.39461538461538,206.32846153846154,208.2623076923077,210.19615384615383,{"y":212.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,185.68307692307692,184.37615384615384,183.06923076923078,181.7623076923077,180.45538461538462,179.14846153846153,177.84153846153848,176.5346153846154,175.2276923076923,173.92076923076922,172.61384615384617,171.30692307692308,{"y":170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":155.59,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.74,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.99,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$250.00

Average Price Target$212.13

Lowest Price Target$170.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$201

Hold

7.29%

Upside

Reiterated

05/31/25

AbbVie's stock score is driven primarily by strong earnings call highlights and solid financial performance, despite high leverage and valuation concerns. The company's strategic investments and guidance adjustments indicate positive long-term growth prospects. However, potential financial risks due to leverage and high P/E ratio warrant cautious optimism.

Terence FlynnMorgan Stanley

Morgan Stanley

$250

Buy

33.45%

Upside

Reiterated

06/03/25

AbbVie's Promising Growth Trajectory: Strong Pipeline, Strategic Investments, and Global Expansion

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

05/31/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD)

Luisa HectorBerenberg Bank

Berenberg Bank

$195→$170

Hold

-9.26%

Downside

Reiterated

05/30/25

Berenberg Bank Sticks to Its Hold Rating for AbbVie (ABBV)

Tim AndersonBank of America Securities

Bank of America Securities

$204

Hold

8.89%

Upside

Reiterated

05/15/25

Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)

Geoff MeachamCiti

Citi

$210→$205

Hold

9.43%

Upside

Downgraded

05/15/25

AbbVie downgraded to Neutral from Buy at CitiAbbVie downgraded to Neutral from Buy at Citi

Nico ChenDBS

DBS

$183

Hold

-2.32%

Downside

Reiterated

05/14/25

AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties

Vamil DivanGuggenheim

Guggenheim

$214→$216

Buy

15.30%

Upside

Reiterated

04/29/25

AbbVie price target raised to $216 from $214 at GuggenheimAbbVie price target raised to $216 from $214 at Guggenheim

David RisingerLeerink Partners

Leerink Partners

$210

Buy

12.10%

Upside

Reiterated

04/28/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD), AbbVie (NYSE: ABBV) and Molecular Partners (NASDAQ: MOLN)

Rajesh KumarHSBC

HSBC

$230→$205

Buy

9.43%

Upside

Reiterated

04/28/25

AbbVie price target lowered to $205 from $230 at HSBCAbbVie price target lowered to $205 from $230 at HSBC

Evan SeigermanBMO Capital

BMO Capital

$215

Buy

14.76%

Upside

Reiterated

04/28/25

BMO Capital reiterates Outperform Rating on Abbvie (ABBV)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $215.00 price target on Abbvie (NYSE: ABBV)

Gary NachmanRaymond James

Raymond James

$220→$227

Buy

21.17%

Upside

Reiterated

04/28/25

AbbVie price target raised to $227 from $220 at Raymond JamesAbbVie price target raised to $227 from $220 at Raymond James

Steve ScalaTD Cowen

TD Cowen

$250

Buy

33.45%

Upside

Reiterated

04/25/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

04/25/25

AbbVie's Strong Financial Performance and Growth Potential Justifies Buy Rating

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$210

Buy

12.10%

Upside

Initiated

04/22/25

AbbVie initiated with an Overweight at Cantor FitzgeraldAbbVie initiated with an Overweight at Cantor Fitzgerald

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$201

Hold

7.29%

Upside

Reiterated

05/31/25

Terence FlynnMorgan Stanley

Morgan Stanley

$250

Buy

33.45%

Upside

Reiterated

06/03/25

AbbVie's Promising Growth Trajectory: Strong Pipeline, Strategic Investments, and Global Expansion

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

05/31/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD)

Luisa HectorBerenberg Bank

Berenberg Bank

$195→$170

Hold

-9.26%

Downside

Reiterated

05/30/25

Berenberg Bank Sticks to Its Hold Rating for AbbVie (ABBV)

Tim AndersonBank of America Securities

Bank of America Securities

$204

Hold

8.89%

Upside

Reiterated

05/15/25

Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)

Geoff MeachamCiti

Citi

$210→$205

Hold

9.43%

Upside

Downgraded

05/15/25

AbbVie downgraded to Neutral from Buy at CitiAbbVie downgraded to Neutral from Buy at Citi

Nico ChenDBS

DBS

$183

Hold

-2.32%

Downside

Reiterated

05/14/25

AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties

Vamil DivanGuggenheim

Guggenheim

$214→$216

Buy

15.30%

Upside

Reiterated

04/29/25

AbbVie price target raised to $216 from $214 at GuggenheimAbbVie price target raised to $216 from $214 at Guggenheim

David RisingerLeerink Partners

Leerink Partners

$210

Buy

12.10%

Upside

Reiterated

04/28/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD), AbbVie (NYSE: ABBV) and Molecular Partners (NASDAQ: MOLN)

Rajesh KumarHSBC

HSBC

$230→$205

Buy

9.43%

Upside

Reiterated

04/28/25

AbbVie price target lowered to $205 from $230 at HSBCAbbVie price target lowered to $205 from $230 at HSBC

Evan SeigermanBMO Capital

BMO Capital

$215

Buy

14.76%

Upside

Reiterated

04/28/25

BMO Capital reiterates Outperform Rating on Abbvie (ABBV)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $215.00 price target on Abbvie (NYSE: ABBV)

Gary NachmanRaymond James

Raymond James

$220→$227

Buy

21.17%

Upside

Reiterated

04/28/25

AbbVie price target raised to $227 from $220 at Raymond JamesAbbVie price target raised to $227 from $220 at Raymond James

Steve ScalaTD Cowen

TD Cowen

$250

Buy

33.45%

Upside

Reiterated

04/25/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

04/25/25

AbbVie's Strong Financial Performance and Growth Potential Justifies Buy Rating

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$210

Buy

12.10%

Upside

Initiated

04/22/25

AbbVie initiated with an Overweight at Cantor FitzgeraldAbbVie initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+3.13%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +3.13% per trade.

3 Months

xxx

Success Rate

18/24 ratings generated profit

Average Return

+7.67%

assigned a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.67% per trade.

1 Year

Christopher RaymondPiper Sandler

Success Rate

37/41 ratings generated profit

Average Return

+22.00%

assigned a buy rating 4 months ago

Copying Christopher Raymond's trades and holding each position for 1 Year would result in 90.24% of your transactions generating a profit, with an average return of +22.00% per trade.

2 Years

xxx

Success Rate

39/41 ratings generated profit

Average Return

+38.39%

assigned a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.12% of your transactions generating a profit, with an average return of +38.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABBV has received 19 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 212.13.

Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.22 with a range of $3.06 to $3.29. The previous quarter’s EPS was $2.46. ABBV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $14.95B with a range of $14.50B to $15.18B. The previous quarter’s sales results were $13.34B. ABBV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 212.13.

What is ABBV’s upside potential, based on the analysts’ average price target?

AbbVie has 13.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABBV a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.

What is AbbVie’s price target?

The average price target for AbbVie is 212.13. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $250.00 ,the lowest forecast is $170.00. The average price target represents 13.23% Increase from the current price of $187.34.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of ABBV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbbVie (ABBV) Stock Forecast & Price Target

ABBV Analyst Ratings

ABBV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

ABBV Analyst Recommendation Trends

ABBV Financial Forecast

ABBV Earnings Forecast

ABBV Sales Forecast

ABBV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts